Ergomed (ERGO)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

878.00p
   
  • Change Today:
      24.00p
  • 52 Week High: 878.00
  • 52 Week Low: 280.00
  • Currency: UK Pounds
  • Shares Issued: 48.72m
  • Volume: 1,421,662
  • Market Cap: £427.74m

Ergomed joins Covid-19 therapy programme

By Josh White

Date: Monday 06 Apr 2020

LONDON (ShareCast) - (Sharecast News) - Specialised pharmaceutical services provider Ergomed announced on Monday that it is providing support for a clinical development programme for 'namilumab', a monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), for the treatment of patients with rapidly worsening Covid-19 coronavirus symptoms.
The AIM-traded firm said the programme was being conducted at the Humanitas Research Hospitals in Bergamo and Milan in Italy, and was supported by Izana Bioscience - an Oxford-based biopharmaceutical company focused on the development of namilumab.

It said it had been "integrally involved" in establishing the programme, drawing on its developing expertise in Covid-19, and the flexibility that underpinned its specialist capabilities, including its site management model in successfully managing complex clinical programmes.

"Research into potential treatments for Covid-19, and particularly the re-purposing of existing therapies and candidates, is imperative if the impact of the pandemic is to be reduced," said executive chairman Dr Miroslav Reljanović.

"We are currently providing clinical, operational and pharmacovigilance services to the re-purposing of three compounds for critically ill patients with Covid-19, demonstrating our ability to respond rapidly to customers' needs at this time.

"As our experience with Covid-19 continues to build, we hope to bring our capabilities and expertise increasingly to bear on this fast moving and critically important field."

At 1604 BST, shares in Ergomed were down 0.1% at 442.06p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ergomed Market Data

Currency UK Pounds
Share Price 878.00p
Change Today 24.00p
% Change 2.81 %
52 Week High 878.00
52 Week Low 280.00
Volume 1,421,662
Shares Issued 48.72m
Market Cap £427.74m

Ergomed Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
86.8% below the market average86.8% below the market average86.8% below the market average86.8% below the market average86.8% below the market average
3.70% above the sector average3.70% above the sector average3.70% above the sector average3.70% above the sector average3.70% above the sector average
Price Trend
96.95% above the market average96.95% above the market average96.95% above the market average96.95% above the market average96.95% above the market average
89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average
Income Not Available
Growth
21.73% above the market average21.73% above the market average21.73% above the market average21.73% above the market average21.73% above the market average
29.73% below the sector average29.73% below the sector average29.73% below the sector average29.73% below the sector average29.73% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Ergomed Dividends

No dividends found

Trades for 30-Nov-2020

Time Volume / Share Price
16:36 6,018 @ 878.00p
14:03 16,807 @ 854.00p
16:56 578,501 @ 878.00p
16:55 2,434 @ 863.03p
16:54 50,000 @ 878.00p

Ergomed Key Personnel

COO Lewis Cameron

Top of Page